Drug Action
Dacomitinib is a tyrosine kinase inhibitor that inhibits epidermal growth factor receptor (EGFR).
PDF page 1052
Loading InternPractice…
Drug reference
Dacomitinib is a tyrosine kinase inhibitor that inhibits epidermal growth factor receptor (EGFR).
PDF page 1052
Non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations (specialist use only) ▶BY MOUTH ▶Adult: 45 mg once daily, for dose adjustments, treatment interruption or discontinuation due to side- effects—consult product literature
PDF page 1052
NICE decisions ▶Dacomitinib for untreated EGFR mutation-positive non-small- cell lung cancer (August 2019) NICE TA595 Dacomitinib (Vizimpro ®) is recommended, within its marketing authorisation, as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) in adults. It is recommended only if the manufacturer provides it according to the commercial arrangement. www.nice.org.uk/guidance/ta595 Scottish Medicines Consortium (SMC) decisions SMC No. SMC2184 The Scottish Medicines Consortium has advised (September 2019) that dacomitinib (Vizimpro ®) is accepted for use within NHS Scotland as monotherapy, for the first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
PDF pages 1052, 1053
→Appendix 1: dacomitinib
PDF page 1052
▶Common or very common Alopecia. appetite decreased. asthenia. dehydration. diarrhoea. dry eye. dry mouth. eye inflammation. hypertrichosis. hypokalaemia. increased risk of infection. interstitial lung disease (discontinue permanently). mucositis. nail discolouration . nail disorders. nausea. oral disorders. oropharyngeal pain. pneumonitis (discontinue permanently). skin reactions. taste altered. vomiting. weight decreased
PDF page 1052
Manufacturer advises females of childbearing potential should use effective contraception during treatment and for at least 17 days after stopping treatment.
PDF page 1052
Manufacturer advises avoid. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 1052
Manufacturer advises avoid—no information available.
PDF page 1052
Manufacturer advises avoid in severe impairment (no information available).
PDF page 1052
Manufacturer advises caution in severe impairment (no information available).
PDF page 1052
Manufacturer advises monitor liver function periodically—interrupt treatment if severe changes in liver function occur.
PDF page 1052
There can be variation in the licensing of different medicines containing the same drug. Tablet A ▶Vizimpro (Pfizer Ltd) Dacomitinib (as Dacomitinib monohydrate) 15 mg Vizimpro 15mg tablets | 30 tablet P £2,703.00 (Hospital only) Dacomitinib (as Dacomitinib monohydrate) 30 mg Vizimpro 30mg tablets | 30 tablet P £2,703.00 (Hospital only) Dacomitinib (as Dacomitinib monohydrate) 45 mg Vizimpro 45mg tablets | 30 tablet P £2,703.00 (Hospital only)
PDF page 1053
Photosensitivity Manufacturer advises patients should wear protective clothing and apply sunscreen before sun exposure. Driving and skilled tasks Manufacturer advises patients and carers should be cautioned on the effects on driving and performance of skilled tasks—increased risk of fatigue and ocular side-effects.
PDF page 1052
45 mg once daily, for dose adjustments,
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1052